Conditions: Cryopyrin-associated Periodic Syndromes Familial Cold Autoinflammatory Syndrome Muckle-Wells Syndrome Neonatal Onset Multisystem Inflammatory Disease
Keywords: Cryopyrin-associated periodic syndromes (CAPS) Familial Cold Autoinflammatory Syndrome (FCAS) Muckle-Wells Syndrome (MWS) or Neonatal Onset Multisystem Inflammatory Disease (NOMID) children systemic autoinflammatory disease CIAS-1 gene NALP-3 NLRP3 ACZ885 Ilaris human monoclonal anti-human interleukin-1 beta (IL-beta) antibody autosomal dominant familial autoinflammatory syndrome
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 17
Healthy volunteers: no

Brief summary:
This trial will assess the safety, efficacy and tolerability of ACZ885 in patients aged 4 years and younger with cryopyrin associated periodic syndromes (CAPS)

Detailed description:

Arms:
arm 1: Canakinumab s.c. injection (2 mg/kg) was administered every 8 weeks.

Interventions: intervention 1: ACZ885
Intervention descriptions: intervention 1: None

Protocol document: